Role of genetics and drug metabolism in human cancer risk

https://doi.org/10.1016/0027-5107(91)90022-GGet rights and content

Abstract

The research field concerning responses to drugs having a hereditary basis is called ‘pharmacogenetics’. At least 5 dozen pharmacogenetic polymorphisms have been described in clinical medicine; many are responsible for marked differences in genetic predisposition toward toxicity or cancer. Three are detailed here: the acetylation, the debrisquine, and the AH locus polymorphism. All 3 are very common among the United States' population: 1 in 2 is a ‘slow acetylator’, 1 in 12 is a ‘poor metabolizer’ for more than 2 dozen commonly prescribed drugs in the debrisoquine panel, and the CYP1A1 and CYP1A2 (cytochromes P1450 and P3450 genes are highly inducible by cigarette smoke in 1 of 10 patients. Differences in xenobiotic metabolism between individuals in the same family can be greater than 200-fold, suggesting that occupationally hazardous chemicals, as well as prescribed drugs having a narrow therapeutic window, might cause strikingly dissimilar effects between patients of differing genotypes. Our ultimate goal is ‘preventive toxicology’, i.e. the development of simple, inexpensive, unequivocal and sensitive assays to predict individual risk of toxicity or cancer. These tests could help the individual in choosing a safer life style or place of work and might aid the physician in deciding which drug to prescribe.

References (62)

  • M.S. Bryant et al.

    Hemoglobin adducts of aromatic amines: Associations with smoking status and type of tobacco

  • N. Caporaso et al.

    Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype

    Cancer Res.

    (1989)
  • N.E. Caporaso et al.

    Lung cancer and the debrisoquine metabolic phenotype

    J. Natl. Cancer Inst.

    (1990)
  • R.A. Cartwright

    Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia

  • R.J. Dern et al.

    The hemolytic effect of primaquine

    J. Lab. Clin. Med.

    (1955)
  • M. Eichelbaum

    Polymorphic drug oxidation in humans

  • D.A.P. Evans et al.

    Genetic control of isoniazid metabolism in man

    Br. Med. J.

    (1960)
  • R.M. Evans

    The steroid and thyroid hormone receptor superfamily

    Science

    (1988)
  • P. Godeau et al.

    Lupus erythemateux dissemine et taux d'isoniazide actif

    Ann. Med. Int.

    (1973)
  • F.J. Gonzalez et al.

    Structural gene products of the Ah locus, Transcriptional regulation of cytochrome P1-450 and P3-450 mRNA levels by 3-methylcholanthrene

    Mol. Pharmacol.

    (1984)
  • F.J. Gonzalez et al.

    Molecular characterization of the common human deficiency in metabolism of debrisoquine and other drugs

    Nature (London)

    (1988)
  • D.M. Grant et al.

    Nucleotide sequence of an intronless gene for human arylamine N-acetyltransferase related to polymorphic drug acetylation

    Nucleic Acids Res.

    (1989)
  • H.P. Hanssen et al.

    Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis

    Eur. Urol.

    (1985)
  • A. Hirono et al.

    Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(−)

  • J.R. Idle et al.

    Polymorphisms of oxidation at carbon centers of drugs and their clinical significance

    Drug Metab. Rev.

    (1979)
  • K. Ikeya et al.

    Human CYP1A2: Sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression

    Mol. Endocrinol.

    (1989)
  • K.F. Ilett et al.

    Acetylation phenotype in colorectal carcinoma

    Cancer Res.

    (1987)
  • A.K. Jaiswal et al.

    Two RFLPs associated with the human P1450 gene linked to the MPI locus on chromosome 15

    Nucleic Acids Res.

    (1986)
  • A.K. Jaiswal et al.

    Human P1-450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism

    Nucleic Acids Res.

    (1985)
  • A. Kaisary et al.

    Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors

    Cancer Res.

    (1987)
  • Cited by (239)

    • Polymorphism of CYP1A1 gene variants rs4646903 and rs1048943 relation to the incidence of cervical cancer in Chhattisgarh

      2017, Environmental Toxicology and Pharmacology
      Citation Excerpt :

      CYP1A1 enzyme is also conscientious for aryl hydrocarbon hydroxylase activity of widespread environmental carcinogens like polyaromatic hydrocarbon, polyaromatic amines, dibenzofurans and biphenyls. Due to the altered CYP1A1 enzyme activity, the substance causes cell damage by forming cell adducts, damage lipids and proteins too (Nebert, 1991). The CYP1A1 gene is present on chromosome 15q22-24 possessing 5987 bp encoding a protein of 512 amino acids (Sowers et al., 2006).

    View all citing articles on Scopus
    View full text